Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 9, 2013, Pages 1460-1465

  Kanno, Yuichiro ^a   Ota, Rumi ^a   Someya, Kousuke ^a   Kusakabe, Taichi ^a   Kato, Keisuke ^a   Inouye, Yoshio ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Androgen receptor; C2C12 cell; Follistatin; Selective androgen receptor modulator

Indexed keywords

17,20 [(1 METHOXYETHYLIDENE)BIS (OXY)] 3 OXO 19 NORPREGNA 4,20 DIENE 21 CARBOXYLIC ACID METHYL ESTER; ANDROGEN RECEPTOR; ANDROSTANOLONE; FOLLISTATIN; MESSENGER RNA; MYOGENIC FACTOR; MYOGENIC FACTOR 5; MYOGENIC FACTOR D; MYOGENIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; YK 11;

ANIMAL CELL; ARTICLE; GENE EXPRESSION; MOLECULAR MECHANICS; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BINDING; REGULATORY MECHANISM;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; CELL DIFFERENTIATION; CELL LINE; FLUTAMIDE; FOLLISTATIN; MICE; MYOBLASTS; MYOD PROTEIN; MYOGENIC REGULATORY FACTOR 5; MYOGENIN; NORPREGNADIENES; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 84884623149     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00231     Document Type: Article

References (34)

1. Bhasin S, Tenover JS. Age-associated sarcopenia-issues in the use of testosterone as an anabolic agent in older men. J. Clin. Endocrinol. Metab., 82, 1659-1660 (1997).
2. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J. Clin. Endocrinol. Metab., 82, 407-413 (1997).
3. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Yarasheski KE, Ulloor J, Colletti P, Roubenoff R, Azen SP. Testosterone and growth hormone improve body composition and muscle performance in older men. J. Clin. Endocrinol. Metab., 94, 1991-2001 (2009).
4. Matsumoto T, Takeyama K, Sato T, Kato S. Study of androgen receptor functions by genetic models. J. Biochem., 138, 105-110 (2005).
5. Matsumoto T, Shiina H, Kawano H, Sato T, Kato S. Androgen receptor functions in male and female physiology. J. Steroid Biochem. Mol. Biol., 109, 236-241 (2008).
6. Matsumoto T, Takeyama K, Sato T, Kato S. Androgen receptor functions from reverse genetic models. J. Steroid Biochem. Mol. Biol., 85, 95-99 (2003).
7. Lee DK, Chang C. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J. Clin. Endocrinol. Metab., 88, 4043-4054 (2003).
8. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signal., 6, e010 (2008).
9. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr. Opin. Clin. Nutr. Metab. Care, 12, 232-240 (2009).
10. Robinson Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. J. Cell Sci., 116, 585-586 (2003).
11. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem., 266, 510-518 (1991).
12. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem., 271, 6379-6388 (1996).
13. Henttu P, Liao SS, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 130, 766-772 (1992).
14. Wolf DA, Schulz P, Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol. Endocrinol., 6, 753-762 (1992).
15. Magee JA, Chang LW, Stormo GD, Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology, 147, 590-598 (2006).
16. Makkonen H, Kauhanen M, Paakinaho V, Jaaskelainen T, Palvimo JJ. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res., 37, 4135-4148 (2009).
17. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J. Urol., 173, 1772-1777 (2005).
18. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry, 36, 1052-1064 (1997).
19. Li J, Fu J, Toumazou C, Yoon HG, Wong J. A role of the aminoterminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol. Endocrinol., 20, 776-785 (2006).
20. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc. Natl. Acad. Sci. U.S.A., 102, 9802-9807 (2005).
21. He B, Lee LW, Minges JT, Wilson EM. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem., 277, 25631-25639 (2002).
22. Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y. (17alpha, 20E)-17, 20-[(1-Methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna- 4, 20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol. Pharm. Bull., 34, 318-323 (2011).
23. Zhu J, Li Y, Lu A, Gharaibeh B, Ma J, Kobayashi T, Quintero AJ, Huard J. Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. Am. J. Pathol., 179, 915-930 (2011).
24. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factorbeta signaling pathways. Endocrinology, 150, 1259-1268 (2009).
25. Perry RL, Rudnick MA. Molecular mechanisms regulating myogenic determination and differentiation. Front. Biosci., 5, D750-D767 (2000).
26. Braga M, Bhasin S, Jasuja R, Pervin S, Singh R. Testosterone inhibits transforming growth factor-beta signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action. Mol. Cell. Endocrinol., 350, 39-52 (2012).
27. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev. Biol., 2, 8 (2002).
28. Tanaka S, Terada K, Nohno T. Canonical Wnt signaling is involved in switching from cell proliferation to myogenic differentiation of mouse myoblast cells. J. Mol. Signal., 6, 12 (2011).
29. Zhang L, Shi S, Zhang J, Zhou F, ten Dijke P. Wnt/beta-catenin signaling changes C2C12 myoblast proliferation and differentiation by inducing Id3 expression. Biochem. Biophys. Res. Commun., 419, 83-88 (2012).
30. He B, Minges JT, Lee LW, Wilson EM. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J. Biol. Chem., 277, 10226-10235 (2002).
31. Quigley CA, Tan JA, He B, Zhou ZX, Mebarki F, Morel Y, Forest MG, Chatelain P, Ritzen EM, French FS, Wilson EM. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction. Mech. Ageing Dev., 125, 683-695 (2004).
32. Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxyl- terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem., 273, 92-101 (1998).
33. Thompson J, Saatcioglu F, Janne OA, Palvimo JJ. Disrupted aminoand carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol. Endocrinol., 15, 923-935 (2001).
34. Furuya K, Yamamoto N, Ohyabu Y, Morikyu T, Ishige H, Albers M, Endo Y. Mechanism of the tissue-specific action of the selective androgen receptor modulator S-101479. Biol. Pharm. Bull., 36, 442-451 (2013).